In addition, the inactivating mutations (or downregulation) of genes in the MHC‐I antigen presentation or IFN‐γ signaling pathways sometimes greatly impair CD8+ T cell‐mediated tumor immunity, and gives rise to the resistance of tumor vaccine.234, 235, 236. This evidence concerns the gene CD8A and neoplasm.